Asteria Health recalled 1,475 estradiol pellets on January 26, 2026, due to potential metal particulate contamination. This recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and seek guidance from their healthcare provider.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Estradiol pellets are used for hormone replacement therapy, primarily in women undergoing menopause. They help alleviate symptoms such as hot flashes and mood swings.
The presence of metal particulate matter in the pellets can lead to serious health risks if ingested, including potential toxicity and adverse reactions.
This recall is not part of a broader industry pattern.
The recall signifies a potential health risk for consumers relying on this medication, necessitating immediate action to prevent possible health complications.
Lot numbers and expiration dates can typically be found on the product packaging or accompanying documentation.
Expect a response regarding refunds or replacements within 4-6 weeks after contacting the manufacturer.
Keep all receipts, communication with the manufacturer, and any medical records related to the use of the recalled product.
The recalled product is Estradiol, 20 mg, 1 Sterile Pellet, with lot number 253000124 and an expiration date of June 2, 2026. It was distributed nationwide in the USA. There are no price details available.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Asteria Health recalled 133 estradiol pellets on January 26, 2026, after detecting potential metal particulate matter. The recall, classified as Class II, affects pellets with lot number 253000126 and an expiration date of June 9, 2026. Consumers must stop using the product immediately and contact their healthcare provider for guidance.
Asteria Health recalled 60,868 testosterone pellets on January 26, 2026, due to contamination risks. The recall affects specific lots of the product that may contain metal particulate matter. Consumers must stop using the product immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,015 testosterone pellets on January 26, 2026 due to potential metal particulate contamination. The recall affects products distributed nationwide in the United States. Consumers must stop using the pellets immediately and contact their healthcare provider for guidance.
Asteria Health recalled 89,074 testosterone pellets on January 26, 2026. The recall stems from potential metal particulate contamination. Consumers must stop using the product and contact their healthcare provider immediately.
Asteria Health recalled 22,478 Estradiol 12.5 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers and healthcare providers must stop using the product immediately. The FDA classified this recall as Class II, indicating a high hazard level.
Asteria Health recalled 24,099 Estradiol, 10 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers should stop using the product immediately. The recall affects pellets distributed nationwide in the USA.
Asteria Health recalled 50,990 Estradiol pellets on January 26, 2026, due to potential metal particulate matter contamination. The recall affects products distributed nationwide in the USA. Consumers should stop using the pellets immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,464 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. The recall affects products distributed nationwide. Consumers must stop using the product immediately and seek guidance from healthcare providers.